=> fil reg
FILE 'REGISTRY' ENTERED AT 12:04:48 ON 10 MAY 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 9 MAY 2003 HIGHEST RN 513416-44-9
DICTIONARY FILE UPDATES: 9 MAY 2003 HIGHEST RN 513416-44-9

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2003

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:
http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

=> d ide can tot l8

L8 ANSWER 1 OF 13 REGISTRY COPYRIGHT 2003 ACS
RN **262429-95-8** REGISTRY
CN Benzenesulfonamide, 4-(dipropylamino)-3,5-dinitro-N-[(trifluoromethyl)sulfonyl]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C13 H17 F3 N4 O8 S2
SR CA
LC STN Files: CA, CAPLUS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1957 TO DATE)
1 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 132:246369

L8 ANSWER 2 OF 13 REGISTRY COPYRIGHT 2003 ACS
RN **262429-94-7** REGISTRY
CN 2H-1-Benzopyran-2-carboxylic acid, 3,4-dihydro-7-(2-naphthalenylmethoxy)-8-propyl- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C24 H24 O4
SR CA
LC STN Files: CA, CAPLUS

Jan Delaval
Reference Librarian
Biotechnology & Chemical Library
CM1 1E07 – 703-308-4498
jan.delaval@uspto.gov



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1957 TO DATE)
1 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 132:246369

L8 ANSWER 3 OF 13 REGISTRY COPYRIGHT 2003 ACS
RN **262429-93-6** REGISTRY
CN 2H-1-Benzopyran-2-carboxylic acid, 3,4-dihydro-8-propyl-7-(2-quinolinylmethoxy)- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C23 H23 N O4
SR CA
LC STN Files: CA, CAPLUS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1957 TO DATE)
1 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 132:246369

L8 ANSWER 4 OF 13 REGISTRY COPYRIGHT 2003 ACS
RN **262429-92-5** REGISTRY
CN Benzenesulfonic acid, 3,5-dichloro-2-hydroxy-, 2,4-dichloro-6-[[[(trifluoromethyl)sulfonyl]amino]sulfonyl]phenyl ester (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C13 H6 Cl4 F3 N O8 S3
SR CA
LC STN Files: CA, CAPLUS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1957 TO DATE)
1 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 132:246369

L8 ANSWER 5 OF 13 REGISTRY COPYRIGHT 2003 ACS
RN **156005-50-4** REGISTRY
CN 2H-1-Benzopyran-2-carboxylic acid, 7-[3-(4-acetyl-2-ethyl-5-hydroxyphenoxy)propoxy]-3,4-dihydro-8-propyl- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C26 H32 O7
CI COM
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

4 REFERENCES IN FILE CA (1957 TO DATE)
4 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 132:246369

REFERENCE 2: 123:188623

REFERENCE 3: 121:141719

REFERENCE 4: 121:57380

L8 ANSWER 6 OF 13 REGISTRY COPYRIGHT 2003 ACS
RN **156005-27-5** REGISTRY
CN 2H-1-Benzopyran-2-carboxylic acid, 7-[3-[2-ethyl-5-hydroxy-4-(1H-pyrazol-3-yl)phenoxy]propoxy]-3,4-dihydro-8-propyl- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C27 H32 N2 O6
SR CA
LC STN Files: CA, CAPLUS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1957 TO DATE)
2 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 132:246369

REFERENCE 2: 121:57380

L8 ANSWER 7 OF 13 REGISTRY COPYRIGHT 2003 ACS
RN **153034-77-6** REGISTRY
CN 9H-Xanthene-4-propanoic acid, 7-carboxy-3-[3-[(5-ethyl-4'-fluoro-2-hydroxy[1,1'-biphenyl]-4-yl)oxy]propoxy]-9-oxo- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 3-[7-Carboxy-9-oxo-3-[3-[2-ethyl-4-(4-fluorophenyl)-5-hydroxyphenoxy]propoxy]-9H-xanthen-4-yl]propanoic acid
CN LY 292728
FS 3D CONCORD
DR 186912-80-1
MF C34 H29 F O9
CI COM
SR CA
LC STN Files: ADISINSIGHT, CA, CAPLUS, DRUGUPDATES, MEDLINE, TOXCENTER, USPATFULL



claim 10 #8
I believe this is "species"

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

20 REFERENCES IN FILE CA (1957 TO DATE)
1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
19 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 135:352783

REFERENCE 2: 134:366682

REFERENCE 3: 134:366681

REFERENCE 4: 134:366680

REFERENCE 5: 134:366679

REFERENCE 6: 132:246369

REFERENCE 7: 129:289931

REFERENCE 8: 129:286007

REFERENCE 9: 129:255009

REFERENCE 10: 129:254996

L8 ANSWER 8 OF 13 REGISTRY COPYRIGHT 2003 ACS
RN **152608-30-5** REGISTRY
CN 2H-1-Benzopyran-2-carboxylic acid, 7-[3-[(5-ethyl-4'-fluoro-2-hydroxy[1,1'-biphenyl]-4-yl)oxy]propoxy]-3,4-dihydro-8-propyl- (9CI) (CA INDEX NAME)
MF C30 H33 F O6
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

12 REFERENCES IN FILE CA (1957 TO DATE)
11 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 134:366684

REFERENCE 2: 134:366682

REFERENCE 3: 134:366681

REFERENCE 4: 134:366680

REFERENCE 5: 134:366679

REFERENCE 6: 132:246369

REFERENCE 7: 129:144547

REFERENCE 8: 126:74591

REFERENCE 9: 125:58323

REFERENCE 10: 124:55467

L8 ANSWER 9 OF 13 REGISTRY COPYRIGHT 2003 ACS
RN **147612-00-8** REGISTRY
CN 2H-1-Benzopyran-2-carboxylic acid, 7-[3-(4-ethoxy-2-ethyl-5-hydroxyphenoxy)propoxy]-3,4-dihydro-8-propyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN LY 282201
FS 3D CONCORD

MF C26 H34 O7
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

7 REFERENCES IN FILE CA (1957 TO DATE)
7 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 134:371777

REFERENCE 2: 134:371774

REFERENCE 3: 134:357589

REFERENCE 4: 132:246369

REFERENCE 5: 123:188623

REFERENCE 6: 120:322935

REFERENCE 7: 118:233824

L8 ANSWER 10 OF 13 REGISTRY COPYRIGHT 2003 ACS
RN **120072-59-5** REGISTRY
CN 2H-1-Benzopyran-2-carboxylic acid, 7-[3-(4-acetyl-3-methoxy-2-propylphenoxy)propoxy]-3,4-dihydro-8-propyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN CGS 24115
CN SC 41390
CN SC 41930
FS 3D CONCORD
DR 157062-25-4
MF C28 H36 O7
SR CA
LC STN Files: ADISINSIGHT, ANABSTR, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAPLUS, CASREACT, CEN, CIN, DDFU, DRUGNL, DRUGU, DRUGUPDATES, EMBASE, MEDLINE, PHAR, PROMT, SYNTHLINE, TOXCENTER, USPAT2, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

56 REFERENCES IN FILE CA (1957 TO DATE)

55 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 137:346175

REFERENCE 2: 136:161356

REFERENCE 3: 134:371777

REFERENCE 4: 134:371774

REFERENCE 5: 134:366684

REFERENCE 6: 134:357589

REFERENCE 7: 132:246369

REFERENCE 8: 132:203175

REFERENCE 9: 130:217617

REFERENCE 10: 127:239120

L8 ANSWER 11 OF 13 REGISTRY COPYRIGHT 2003 ACS
RN **97582-55-3** REGISTRY
CN 4H-1-Benzopyran-2-carboxylic acid, 7-[(4-acetyl-3-hydroxy-2-propylphenyl)methoxy]-4-oxo-8-propyl- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C25 H26 O7
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1957 TO DATE)
2 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 132:246369

REFERENCE 2: 103:141966

L8 ANSWER 12 OF 13 REGISTRY COPYRIGHT 2003 ACS
RN **145-63-1** REGISTRY
CN 1,3,5-Naphthalenetrisulfonic acid, 8,8'-[carbonylbis[imino-3,1-phenylenecarbonylimino(4-methyl-3,1-phenylene)carbonylimino]]bis- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 1,3,5-Naphthalenetrisulfonic acid, 8,8'-[ureylenebis[m-phenylenecarbonylimino(4-methyl-m-phenylene)carbonylimino]]di- (8CI)
OTHER NAMES:
CN 8,8'-[Ureylenebis[m-phenylenecarbonylimino(4-methyl-m-phenylene)carbonylimino]]di-1,3,5-naphthalenetrisulfonic acid

CN Farma
CN Farma 939
CN Fourneau
CN Naganol
CN Suramin
CN Suramine
MF C51 H40 N6 O23 S6
CI COM
LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, AQUIRE, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CABA, CANCERLIT, CAOLD, CAPLUS, CBNB, CHEMCATS, CHEMLIST, CIN, DDFU, DRUGNL, DRUGU, DRUGUPDATES, EMBASE, IPA, MEDLINE, NAPRALERT, NIOSHTIC, PHAR, PROMT, RTECS*, SYNTHLINE, TOXCENTER, TULSA, USAN, USPAT2, USPATFULL, VETU
(*File contains numerically searchable property data)
Other Sources: EINECS**
(**Enter CHEMLIST File for up-to-date regulatory information)

PAGE 1-A



PAGE 1-B



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1254 REFERENCES IN FILE CA (1957 TO DATE)
34 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
1258 REFERENCES IN FILE CAPLUS (1957 TO DATE)

3 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 138:297974

REFERENCE 2: 138:292791

REFERENCE 3: 138:281082

REFERENCE 4: 138:265631

REFERENCE 5: 138:260539

REFERENCE 6: 138:248486

REFERENCE 7: 138:233948

REFERENCE 8: 138:233209

REFERENCE 9: 138:231331

REFERENCE 10: 138:215615

L8 ANSWER 13 OF 13 REGISTRY COPYRIGHT 2003 ACS
RN **130-85-8** REGISTRY
CN 2-Naphthalenecarboxylic acid, 4,4'-methylenebis[3-hydroxy- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 2-Naphthoic acid, 4,4'-methylenebis[3-hydroxy- (6CI, 7CI, 8CI)
OTHER NAMES:
CN 2,2'-Dihydroxy-1,1'-dinaphthylmethane-3,3'-dicarboxylic acid
CN 4,4'-Methylenebis[3-hydroxy-2-naphthoic acid]
CN Bis(2-hydroxy-3-carboxy-1-naphthyl)methane
CN Embonic acid
CN Pamoic acid
FS 3D CONCORD
DR 122541-93-9, 67232-45-5, 50857-36-8, 108626-78-4, 47620-91-7
MF C23 H16 O6
CI COM
LC STN Files: ANABSTR, BEILSTEIN*, BIOSIS, BIOTECHNO, CA, CAOLD, CAPLUS, CASREACT, CHEMCATS, CHEMLIST, CSCHEM, DDFU, DRUGU, EMBASE, HODOC*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, RTECS*, TOXCENTER, USPATFULL
(*File contains numerically searchable property data)
Other Sources: EINECS**, NDSL**, TSCA**
(**Enter CHEMLIST File for up-to-date regulatory information)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

135 REFERENCES IN FILE CA (1957 TO DATE)
13 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
136 REFERENCES IN FILE CAPLUS (1957 TO DATE)
5 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 138:158821

REFERENCE 2: 138:44717

REFERENCE 3: 138:5645

REFERENCE 4: 137:10997

REFERENCE 5: 136:309958

REFERENCE 6: 136:273213

REFERENCE 7: 136:249165

REFERENCE 8: 136:189380

REFERENCE 9: 136:70079

REFERENCE 10: 135:226993

=> fil hcaplus
FILE 'HCAPLUS' ENTERED AT 12:05:06 ON 10 MAY 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 10 May 2003 VOL 138 ISS 20
FILE LAST UPDATED: 9 May 2003 (20030509/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l8
L35 1473 L8

=> s l35 and l1,l2
L36 1 L35 AND (L1 OR L2)

=> s l35 and l3
L37 2 L35 AND L3

=> s l36,l37
L38 2 (L36 OR L37)

=> d all hitstr tot

L38 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2003 ACS
AN 2000:209933 HCAPLUS
DN 132:246369
TI Use of non-peptidyl compounds for the treatment of insulin-related ailments
IN **Helmerhorst, Erik; Plewright, Brian Scott**
PA **Curtin University of Technology, Australia**
SO PCT Int. Appl., 129 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM A61K038-28
ICS A61K031-19; A61K031-35
CC 1-10 (Pharmacology)
Section cross-reference(s): 2, 63

Appl.

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2000016798	A1	20000330	WO 1999-AU786	19990917
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2345155	AA	20000330	CA 1999-2345155	19990917
AU 9960707	A1	20000410	AU 1999-60707	19990917
EP 1115422	A1	20010718	EP 1999-947113	19990917
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
PRAI AU 1998-6091	A	19980922		
WO 1999-AU786	W	19990917		

OS MARPAT 132:246369
AB The present invention relates to the use of at least a non-peptidyl compd. as a biol. modulator of insulin activity or insulin-related activity for the treatment of insulin-related diseases. Non-peptidyl compds. of the present invention exert their effects by mimicking amino acids spatially located on insulin, enabling those compds. to bind to the insulin receptor or insulin-like receptor causing biol. modulation of the activity of the receptor. A method for identifying a non-peptidyl compd. comprises the steps of: (1) comparing the 3D structure of the non-peptidyl compd. with a 3D pharmacophore of an active site of insulin, and (2) selecting a non-peptidyl compd. The compds. may act either as agonists or antagonists of insulin or insulin-like activity. Pharmaceutical compns. contg. chem. compds. capable of modulating the biol. activity of insulin are also claimed. For example, 4,4'-methylenebis[3-hydroxy-2-naphthalenecarboxylic acid] (IM 025) was an antagonist of insulin action. IM 025 caused a dose-dependent decrease in the incorporation of 32P into FYF peptide in insulin-stimulated tubes and inhibited glucose transport in 3T3L1 cells, with IC50 of 150 and 170 .mu.M, resp. 2,4-Dichloro-6-[N-(trifluoromethanesulfonyl)sulfamoylphenyl-3,5-dichloro-2-hydroxybenzene] sulfonate (IM 103) was an agonist of insulin action displaying a biphasic biol. dose response curve with an apex at concn. of 110 .mu.M and an apparent EC50 of 45 .+-. 7 .mu.M.
ST nonpeptidyl insulin receptor agonist antagonist antidiabetic
IT Antidiabetic agents
Pharmacophores

(non-peptidyl compds. modulating insulin activity by mimicking amino acid residues spatially located on insulin and binding to insulin receptors)

IT Insulin receptors
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(non-peptidyl compds. modulating insulin activity by mimicking amino acid residues spatially located on insulin and binding to insulin receptors)

IT **130-85-8 145-63-1 97582-55-3**
120072-59-5 147612-00-8 152608-30-5
153034-77-6 156005-27-5 156005-50-4
262429-92-5 262429-93-6 262429-94-7
262429-95-8
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(non-peptidyl compds. modulating insulin activity by mimicking amino acid residues spatially located on insulin and binding to insulin receptors)

IT 9004-10-8, Insulin, biological studies
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(non-peptidyl compds. modulating insulin activity by mimicking amino acid residues spatially located on insulin and binding to insulin receptors)

RE.CNT 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE
(1) Aguilar-Bryan, L; J Biol Chem 1990, P8218 HCAPLUS
(2) Bahn, H; 1978, P5
(3) Djuric, S; J Med Chem 1989, V32(6), P1145 HCAPLUS
(4) Eli Lilley And Company; EP 132366 1985 HCAPLUS
(5) Eli Lilley And Company; WO 9517183 1995 HCAPLUS
(6) Harper, R; J Med Chem 1994, V37, P2411 HCAPLUS
(7) Mount Sinai School Of Medicine; AU 9055415 1990 HCAPLUS
(8) Novo Nordisk AS; AU 8654495 1986 HCAPLUS
(9) Novo Nordisk AS; AU 8662066 1987 HCAPLUS
(10) Novo Nordisk AS; AU 8813976 1988 HCAPLUS
(11) Novo Nordisk AS; AU 8822636 1990 HCAPLUS
(12) Novo Nordisk AS; AU 9048344 1990 HCAPLUS
(13) Sawyer, J; J Med Chem 1993, V36, P3982 HCAPLUS

IT **130-85-8 145-63-1 97582-55-3**
120072-59-5 147612-00-8 152608-30-5
153034-77-6 156005-27-5 156005-50-4
262429-92-5 262429-93-6 262429-94-7
262429-95-8
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(non-peptidyl compds. modulating insulin activity by mimicking amino acid residues spatially located on insulin and binding to insulin receptors)

RN 130-85-8 HCAPLUS
CN 2-Naphthalenecarboxylic acid, 4,4'-methylenebis[3-hydroxy- (9CI) (CA INDEX NAME)



RN 145-63-1 HCAPLUS
CN 1,3,5-Naphthalenetrisulfonic acid, 8,8'-[carbonylbis[imino-3,1-phenylenecarbonylimino(4-methyl-3,1-phenylene)carbonylimino]]bis- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 97582-55-3 HCAPLUS
CN 4H-1-Benzopyran-2-carboxylic acid, 7-[(4-acetyl-3-hydroxy-2-propylphenyl)methoxy]-4-oxo-8-propyl- (9CI) (CA INDEX NAME)



RN 120072-59-5 HCAPLUS
CN 2H-1-Benzopyran-2-carboxylic acid, 7-[3-(4-acetyl-3-methoxy-2-propylphenoxy)propoxy]-3,4-dihydro-8-propyl- (9CI) (CA INDEX NAME)



RN 147612-00-8 HCAPLUS
CN 2H-1-Benzopyran-2-carboxylic acid, 7-[3-(4-ethoxy-2-ethyl-5-hydroxyphenoxy)propoxy]-3,4-dihydro-8-propyl- (9CI) (CA INDEX NAME)



RN 152608-30-5 HCAPLUS
CN 2H-1-Benzopyran-2-carboxylic acid, 7-[3-[(5-ethyl-4'-fluoro-2-hydroxy[1,1'-biphenyl]-4-yl)oxy]propoxy]-3,4-dihydro-8-propyl- (9CI) (CA INDEX NAME)



RN 153034-77-6 HCAPLUS
CN 9H-Xanthene-4-propanoic acid, 7-carboxy-3-[3-[(5-ethyl-4'-fluoro-2-hydroxy[1,1'-biphenyl]-4-yl)oxy]propoxy]-9-oxo- (9CI) (CA INDEX NAME)



RN 156005-27-5 HCAPLUS
CN 2H-1-Benzopyran-2-carboxylic acid, 7-[3-[2-ethyl-5-hydroxy-4-(1H-pyrazol-3-yl)phenoxy]propoxy]-3,4-dihydro-8-propyl- (9CI) (CA INDEX NAME)



RN 156005-50-4 HCAPLUS
CN 2H-1-Benzopyran-2-carboxylic acid, 7-[3-(4-acetyl-2-ethyl-5-hydroxyphenoxy)propoxy]-3,4-dihydro-8-propyl- (9CI) (CA INDEX NAME)



RN 262429-92-5 HCAPLUS
CN Benzenesulfonic acid, 3,5-dichloro-2-hydroxy-, 2,4-dichloro-6-[[[(trifluoromethyl)sulfonyl]amino]sulfonyl]phenyl ester (9CI) (CA INDEX NAME)



RN 262429-93-6 HCAPLUS
CN 2H-1-Benzopyran-2-carboxylic acid, 3,4-dihydro-8-propyl-7-(2-quinolinylmethoxy)- (9CI) (CA INDEX NAME)



RN 262429-94-7 HCAPLUS
CN 2H-1-Benzopyran-2-carboxylic acid, 3,4-dihydro-7-(2-naphthalenylmethoxy)-8-propyl- (9CI) (CA INDEX NAME)



RN 262429-95-8 HCAPLUS
CN Benzenesulfonamide, 4-(dipropylamino)-3,5-dinitro-N-[(trifluoromethyl)sulfonyl]- (9CI) (CA INDEX NAME)



L38 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2003 ACS
AN 1996:691513 HCAPLUS
DN 126:28763
TI A novel in vitro assay for human angiogenesis
AU Brown, Kathryn J.; Maynes, Susan F.; Bezos, Anna; Maguire, Deborah J.; Ford, Miriam D.; Parish, Christopher R.
CS John **Curtin** School Medical Research, Australian National University, Canberra, 2601, Australia
SO Laboratory Investigation (1996), 75(4), 539-555
CODEN: LAINAW; ISSN: 0023-6837
PB Williams & Wilkins
DT Journal
LA English
CC 9-16 (Biochemical Methods)
AB Angiogenesis, the development of new blood vessels, is an important process in tissue development and wound healing but becomes pathol. when assocd. with solid tumor growth, proliferative retinopathies, and rheumatoid arthritis. To date, there has not been a physiol. relevant in vitro model for human angiogenesis that can be used to screen for enhancers and inhibitors of human angiogenesis and allow further investigation of this process. Initially, culture conditions were established for the induction of human angiogenesis in vitro using fragments of human placental blood vessel. Once the assay was validated, it was examd. for its ability to detect known inhibitors and enhancers of angiogenesis. The role of endogenous acidic fibroblast growth factor (aFGF), basic fibroblast growth factor (bFGF), and vascular endothelial

growth factor (VEGF) in the angiogenic response was also assessed by performing RT-PCR on both the parent vessel and microvessel outgrowths. In addn., neutralizing antibodies against the three growth factors were used to quantify the relative importance of each growth factor in the angiogenic response. A fragment of human placental blood vessel was embedded in a fibrin gel in microculture plates and was found to give rise to a complex network of microvessels during a period of 7 to 21 days in culture. The response did not require the addn. of exogenous growth factors, and thus provides a convenient system for testing substances for their ability to stimulate or inhibit a human in vitro angiogenic response. The ability of the well known angiogenesis antagonist, hydrocortisone, in the presence and absence of heparin, and suramin to significantly inhibit the angiogenic response indicated that the model could be used as an efficient in vitro assay for screening inhibitors of human angiogenesis. The presence of mRNA for aFGF, bFGF, and three isoforms of VEGF, as well as their receptors, FGFR1, FGFR2, Flt-1, and KDR, in vessel outgrowths and the parent vessel, as identified by RT-PCR, strongly implicated aFGF, bFGF, and VEGF as having an important role in this neovascularization response. This was further confirmed by the ability of neutralizing antibodies to aFGF, bFGF, and VEGF to inhibit the angiogenic response to varying extent. Furthermore, the response could be enhanced by the addn. of these growth factors in serum-starved cultures. Finally, a stimulatory effect was obsd. when matrigel was incorporated into the fibrin gel, which indicates that components of the extracellular matrix also play an important role in governing the strength of the angiogenic response. A physiol. angiogenic response relevant to wound healing can be generated by culturing fragments of human placental blood vessels in fibrin gels. The growth factors aFGF, bFGF, and VEGF were shown to play an important role in stimulating this spontaneous angiogenic response. This assay, which can be performed in microcultures, was also shown to be an excellent method for screening for potential inhibitors and enhancers of human angiogenesis.

ST assay angiogenesis

IT Blood vessel
PCR (polymerase chain reaction)
(a novel in vitro assay for human angiogenesis)

IT Receptors
RL: ANT (Analyte); ANST (Analytical study)
(a novel in vitro assay for human angiogenesis)

IT mRNA
RL: ANT (Analyte); BOC (Biological occurrence); BSU (Biological study, unclassified); ANST (Analytical study); BIOL (Biological study); OCCU (Occurrence)
(a novel in vitro assay for human angiogenesis)

IT Blood vessel
(microvessel; a novel in vitro assay for human angiogenesis)

IT Antibodies
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(neutralizing; a novel in vitro assay for human angiogenesis)

IT 106096-92-8, Acidic fibroblast growth factor 106096-93-9, Basic fibroblast growth factor 127464-60-2, Vascular endothelial growth factor
RL: ANT (Analyte); BOC (Biological occurrence); BSU (Biological study, unclassified); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); OCCU (Occurrence); USES (Uses)
(a novel in vitro assay for human angiogenesis)

IT 50-23-7, Hydrocortisone **145-63-1**, Suramin 9005-49-6, Heparin, biological studies
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(a novel in vitro assay for human angiogenesis)

IT **145-63-1**, Suramin
RL: BAC (Biological activity or effector, except adverse); BSU (Biological

study, unclassified); BIOL (Biological study)
(a novel in vitro assay for human angiogenesis)
RN 145-63-1 HCAPLUS
CN 1,3,5-Naphthalenetrisulfonic acid, 8,8'-[carbonylbis[imino-3,1-phenylenecarbonylimino(4-methyl-3,1-phenylene)carbonylimino]]bis- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



=> d all hitstr

L67 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2003 ACS
AN 1993:6982 HCAPLUS
DN 118:6982
TI Preparation of [(heterocyclyl)(alkyl)]phenyl amidines and guanidines as hypoglycemics.
IN Gopalan, Balasubramanian
PA Boots Co., PLC, UK
SO Faming Zhuanli Shenqing Gongkai Shuomingshu, 123 pp.
CODEN: CNXXEV
DT Patent
LA Chinese
IC ICM C07D211-56

ICS C07D207-14; C07D233-02; C07D239-04; C07D265-30; C07D223-12
CC 28-13 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): **1, 63**
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	CN 1057648	A	19920108	CN 1990-103295	19900629
	CN 1037346	B	19980211		
PRAI	CN 1990-103295		19900629		

OS CASREACT 118:6982; MARPAT 118:6982
GI



I

AB The title compds. [I; R1, R2 = (methoxy) aliph. hydrocarbyl, cycloalkyl; or NR1R2 = N-contg. heterocyclyl; R3 = alkyl, cycloalkyl, (substituted) amino; R5 = (methoxy) aliph. hydrocarbyl; R6 = H, (substituted) alkyl, cycloalkyl; R7 = H,alkyl, halo, methoxy, CO2Me, SO2Me; R3R5 may form part of a ring; with provisos] are prepd. E.g., 1-benzyl-3-methyl-2-pyrrolidinone in benzene contg. POCl3 was heated with 4-(2-aminophenyl)morpholine at 70.degree. for 24 h to give 4-[2-(1-benzyl-3-methyl-2-pyrrolidinylideneamino)phenyl]morpholine. This decreased the blood sugar level by .gtoreq.25% in rats 2 or 4 h after they were injected s.c. with **glucose**. Pharmaceuticals contg. I were formulated.

ST amidine heterocyclylalkylphenyl prepn hypoglycemic; guanidine heterocyclylalkylphenyl prepn hypoglycemic; heterocyclylalkylphenyl amidine guanidine; hypoglycemic amidine guanidine

IT **Antidiabetics and Hypoglycemics**
([(heterocyclyl)(alkyl)]phenyl amidines and guanidines)

IT Amidines
RL: SPN (Synthetic preparation); PREP (Preparation)
(aryl, prepn. of, as hypoglycemics)

IT 131679-02-2, N-(2-Morpholinomethylphenyl)morpholine-4-formamidine difumarate
RL: RCT (Reactant); RACT (Reactant or reagent)
(234prepn. of, as hypoglycemic)

IT 131675-72-4P, 4-[2-(2-Piperidinylideneamino)phenyl]morpholine
131675-74-6P, 4-[2-(1-Methyl-2-piperidinylideneamino)phenyl]morpholine
131675-75-7P 131675-76-8P 131675-77-9P 131675-78-0P 131675-80-4P
131675-81-5P 131675-82-6P 131675-83-7P, 4-[2-(1,3,3-Trimethyl-2-pyrrolidinylideneamino)phenyl]morpholine 131675-84-8P 131675-86-0P
131675-87-1P 131675-88-2P 131675-90-6P 131675-91-7P 131675-93-9P
131675-94-0P 131675-95-1P 131675-96-2P 131675-97-3P 131675-98-4P
131675-99-5P 131676-01-2P 131676-02-3P, 4-[4-Chloro-2-(2-piperidinylideneamino)phenyl]morpholine 131676-03-4P 131676-04-5P
131676-05-6P 131676-06-7P 131676-07-8P 131676-08-9P 131676-09-0P
131676-10-3P 131676-13-6P 131676-14-7P, 4-[2-(3-Methyl-2-pyrrolidinylideneamino)phenyl]morpholine fumarate 131676-15-8P
131676-16-9P 131676-17-0P, 1-Butyl-2-(2-morpholinophenyl)-3-acetamidine
131676-19-2P 131676-21-6P 131676-23-8P 131676-25-0P 131676-26-1P
131676-27-2P 131676-28-3P 131676-29-4P 131676-30-7P 131676-31-8P
131676-32-9P 131676-33-0P 131676-34-1P 131676-35-2P 131676-36-3P
131676-37-4P 131676-38-5P 131676-39-6P 131676-40-9P 131676-41-0P
131676-42-1P 131676-43-2P 131676-44-3P 131676-45-4P 131676-46-5P
131676-47-6P 131676-48-7P 131676-49-8P 131676-50-1P 131676-51-2P

131676-52-3P 131676-53-4P 131676-54-5P 131676-55-6P 131676-56-7P
131676-57-8P 131676-59-0P 131676-60-3P 131676-62-5P 131676-63-6P
131676-64-7P 131676-65-8P 131676-66-9P 131676-67-0P 131676-69-2P
131676-70-5P 131676-71-6P 131676-72-7P 131676-73-8P 131676-74-9P
131676-75-0P 131676-77-2P 131676-78-3P, N-(2-
Morpholinophenyl)acetamidine 131676-79-4P, N-(5-Methyl-2-
morpholinophenyl)acetamidine 131676-80-7P, N-(2-
Morpholinophenyl)propionamidine 131676-81-8P, N-(2-
Morpholinophenyl)butyramidine 131676-83-0P, N-(2-
Morpholinophenyl)isobutyramidine 131676-85-2P, N-(5-Fluoro-2-
morpholinophenyl)isobutyramidine 131676-86-3P, N-(2-
Morpholinophenyl)pentanamidine 131676-87-4P, N-(2-
Morpholinophenyl)neopentanamidine 131676-88-5P 131676-89-6P
131676-90-9P 131676-91-0P 131676-94-3P 131676-97-6P 131676-98-7P
131676-99-8P 131677-00-4P 131677-01-5P, 4-(2-[1-(2-Cyanoethyl)-2-
piperidinylideneamino]phenyl)morpholine 131677-02-6P,
4-[2-(3-Morpholinylideneamino)phenyl]morpholine hydrochloride
131677-05-9P 131677-06-0P 131677-08-2P, 4-[2-(1,3-Dimethyl-2-
imidazolidinylideneamino)phenyl]morpholine 131677-09-3P 131677-10-6P
131677-11-7P 131677-12-8P 131677-13-9P 131677-14-0P 131677-15-1P
131677-17-3P 131677-18-4P 131677-20-8P 131677-22-0P 131677-23-1P
131677-24-2P 131677-26-4P 131677-28-6P 131677-29-7P 131677-30-0P
131677-31-1P 131677-35-5P 131677-36-6P, 1-Ethyl-2-(2-morpholinophenyl)-
1,3,3-trimethylguanidine 131677-37-7P, 1-Allyl-2-(2-morpholinophenyl)-
1,3,3-trimethylguanidine 131677-38-8P, 1-Butyl-2-(2-morpholinophenyl)-
1,3,3-trimethylguanidine 131677-39-9P, 1-Pentyl-2-(2-morpholinophenyl)-
1,3,3-trimethylguanidine 131677-40-2P, 4-(2-[1-Methyl-3-(2-methoxyethyl)-
2-imidazolidinylideneamino]phenyl)morpholine 131677-41-3P,
4-(2-[1-Methyl-3-(2-methoxyethyl)-2-imidazolidinylideneamino]phenyl)morpho
line monofumarate 131677-42-4P, 4-(2-[1-Methyl-3-(2-hydroxyethyl)-2-
imidazolidinylideneamino]phenyl)morpholine 131677-43-5P,
N,N-Dimethyl-N'-(2-morpholinophenyl)morpholine-4-formamidine
131677-44-6P 131677-45-7P, 4-[2-(1,3-Dimethyl-2-
imidazolidinylideneamino)phenyl]thiamorpholine 1-oxide 131677-46-8P,
4-[2-(2-Imidazolidenylideneamino)phenyl]morpholine 131677-47-9P,
4-[2-(1-Methyl-2-imidazolidinylideneamino)phenyl]morpholine 131677-48-0P
131677-49-1P 131677-50-4P 131677-51-5P 131677-52-6P 131677-53-7P
131677-54-8P 131677-55-9P 131677-56-0P 131677-58-2P 131677-59-3P
131677-60-6P 131677-61-7P 131677-62-8P 131677-63-9P 131677-64-0P
131677-65-1P 131677-66-2P 131677-67-3P 131677-68-4P 131677-69-5P
131677-70-8P 131677-71-9P 131677-72-0P 131677-73-1P 131677-74-2P
131677-75-3P 131677-76-4P 131677-77-5P 131677-78-6P 131677-79-7P
131677-80-0P 131677-81-1P, 4-[2-(4-Methyl-2-
imidazolidinylideneamino)phenyl]morpholine 131677-82-2P,
4-[2-(4,5-Dimethyl-2-imidazolidinylideneamino)phenyl]morpholine
131677-83-3P, 4-[2-(4,5-Dimethyl-1-(2-hydroxyethyl)-2-
imidazolidinylideneamino)phenyl]morpholine 131677-84-4P,
4-[2-(1-Methylperhydropyrimidin-2-ylideneamino)phenyl]morpholine
131677-85-5P, 2-(2-Morpholinophenylimino)-1,3-diazacycloheptane
131677-86-6P, 1,1-Dimethyl-2-(morpholinophenyl)guanidine 131677-87-7P,
1,3-Dimethyl-2-(morpholinophenyl)guanidine 131677-88-8P,
1,3,3-Trimethyl-2-(2-morpholinophenyl)guanidine 131677-89-9P,
1-Ethyl-2-(2-morpholinophenyl)-3-methylguanidine 131677-90-2P,
1,3-Diethyl-2-(2-morpholinophenyl)guanidine 131677-91-3P,
4-(2-[1-(2-Acetoxyethyl)-2-imidazolidinylideneamino]phenyl)morpholine
131677-93-5P, 1-Butyl-2-(2-morpholinophenyl)-3-methylguanidine
131677-94-6P, 1-(2-Methoxyethyl)-2-(2-morpholinophenyl)guanidine
131677-96-8P, 1-(2-Methylthioethyl)-2-(2-morpholinophenyl)guanidine
131677-97-9P 131677-98-0P, 1-Propyl-2-morpholinophenyl-3-methylguanidine
monofumarate 131677-99-1P, 1-Methyl-2-(2-morpholinophenyl)-3-(2-
methoxyethyl)guanidine 131678-01-8P, 1-Cyclopentyl-2-(2-
morpholinophenyl)-3-methylguanidine 131678-02-9P, 1-Cyclopenyl-2-(2-
morpholinophenyl)-3-methylguanidine monofumarate 131678-03-0P,

N-Methyl-N'-(2-morpholinophenyl)pyrrolidine-1-formamidine 131678-08-5P, 1,3-Dimethyl-2-(5-methyl-2-morpholinophenyl)guanidine fumarate 131678-09-6P, 4-(2-[1-(2-Hydroxyethyl)-2-imidazolidinylideneamino]-4-methylphenyl)morpholine 131678-12-1P, 1-Butyl-2-(5-methyl-2-morpholinophenyl)-3-methylguanidine 131678-13-2P 131678-14-3P 131678-15-4P 131678-16-5P 131678-17-6P 131678-18-7P 131678-19-8P, 1,1-Dimethyl-2-(5-cyano-2-morpholinophenyl)guanidine 131678-20-1P, 1,3-Dipropyl-2-(2-morpholinophenyl)guanidine 131678-21-2P, 1,3-Dipropyl-2-(2-morpholinophenyl)guanidine hemifumarate 131678-22-3P 131678-23-4P 131678-24-5P 131678-25-6P 131678-26-7P 131678-27-8P 131678-28-9P 131678-29-0P 131678-30-3P 131678-31-4P 131678-32-5P 131678-33-6P 131678-35-8P 131678-36-9P 131678-38-1P 131678-39-2P 131678-40-5P 131678-41-6P 131678-43-8P 131678-44-9P 131678-45-0P 131678-46-1P, 1,1-Dimethyl-2-(5-methoxycarbonyl-2-morpholinophenyl)guanidine 131678-47-2P 131678-48-3P 131678-49-4P 131678-50-7P 131678-51-8P 131678-52-9P 131678-53-0P 131678-54-1P 131678-55-2P 131678-56-3P

RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, as hypoglycemic)

IT 131678-57-4P 131678-58-5P 131678-59-6P, 1,1-Dimethyl-2-(5-chloro-2-morpholinophenyl)guanidine 131678-60-9P, 1,1-Dimethyl-2-(5-fluoro-2-morpholinophenyl)guanidine 131678-61-0P, 1,1-Dimethyl-2-(3-methyl-2-morpholinophenyl)guanidine 131678-62-1P, 1,1-Dimethyl-2-(5-isobutyl-2-morpholinophenyl)guanidine 131678-63-2P, 1,1-Dimethyl-2-(5-methylsulfinyl-2-morpholinophenyl)guanidine 131678-64-3P 131678-65-4P 131678-66-5P 131678-67-6P 131678-70-1P 131678-71-2P 131678-72-3P, 4-(2-[1-(2-Hydroxyethyl)-2-imidazolidinylideneamino]phenyl)morpholine monotartrate 131678-74-5P, 1,1-Dimethyl-2-(2-morpholinophenyl)guanidine monotartrate 131678-75-6P, 1,1-Dimethyl-2-(5-methyl-2-morpholinophenyl)guanidine monohydrochloride 131678-76-7P, 1,1-Dimethyl-2-(2-morpholinophenyl)guanidine monohydrochloride 131678-78-9P, 4-[4-Chloro-2-(1,3-dimethyl-2-imidazolidinylideneamino)benzyl]morpholine 131678-79-0P, 4-[4-Chloro-2-(1,3-dimethyl-2-imidazolidinylideneamino)benzyl]morpholine monofumarate 131678-80-3P, N-(2-Morpholinomethylphenyl)morpholine-4-formamidine 131678-81-4P, N-(2-Morpholinophenyl)neopentanamidine monofumarate 131678-84-7P, N-Methyl-N'-(2-morpholinomethylphenyl)neopentanamidine 131678-85-8P, 4-(2-[1-(2-Benzoyloxyethyl)-3-methyl-2-imidazolidinylideneamino]phenyl)morpholine 131678-87-0P, 4-[2-(1-Isopropyl-4,4-dimethyl-2-imidazolidinylideneamino)phenyl]morpholine 131678-88-1P, 1-(2-Methoxyethyl)-2-(2-morpholinophenyl)guanidine fumarate 131678-89-2P, N-Methyl-N'-(2-morpholinophenyl)pyrrolidine-1-formamidine monofumarate 131678-90-5P, 1-Butyl-2-(2-morpholinophenyl)-3-ethylguanidine monofumarate 131678-92-7P, 1-Butyl-2-(5-methyl-2-morpholinophenyl)-3-methylguanidine monofumarate 131678-93-8P, 1-Butyl-2-(6-methyl-2-morpholinophenyl)-3-methylguanidine 131678-94-9P, 1-Butyl-2-(6-methyl-2-morpholinomethyl)-3-methylguanidine monofumarate 131678-95-0P, 1,1-Dimethyl-2-(2-morpholino-5-trifluoromethylphenyl)guanidine fumarate 131678-96-1P, 1,1-Dimethyl-2-(5-cyano-2-morpholinophenyl)guanidine monofumarate 131678-98-3P, 1,1-Dimethyl-2-(5-chloro-2-morpholinophenyl)guanidine monofumarate 131678-99-4P, 1,1-Dimethyl-2-(5-fluoro-2-morpholinophenyl)guanidine fumarate 131679-00-0P, 1,1-Dimethyl-2-(3-methyl-2-morpholinophenyl)guanidine fumarate 131679-01-1P, N,N-Dimethyl-N'-(2-morpholinomethylphenyl)guanidine 131679-03-3P, 4-[2-(1-Benzyl-3-methyl-2-pyrrolidinylideneamino)phenyl]morpholine 131679-07-7P, 4-(2-[1-Methyl-3-(2-acetoxyethyl)-2-imidazolidenylideneamino]phenyl)morpholine 131679-37-3P, 1-Butyl-3-(5-chloro-2-morpholinophenyl)thiourea 131679-38-4P 131679-40-8P 131679-42-0P 131679-45-3P, 1,1-Dimethyl-2-(2-morpholinophenyl)thiourea 131679-46-4P, 2-Methyl-1-(2-morpholinophenyl)-3,3-dimethyl-2-thiopseudourea 131697-93-3P 131697-94-4P 131697-95-5P 131697-96-6P 131697-97-7P 131697-98-8P 131697-99-9P, 4-[2-(1-Isopropyl-4,4-dimethyl-2-

imidazolidenylideneamino)phenyl]morpholine monofumarate 131698-00-5P 131698-01-6P 131698-02-7P, 1,1-Dimethyl-2-(4-methoxy-2-morpholinophenyl)guanidine 143803-94-5P 143803-95-6P 143803-96-7P 143803-99-0P 143804-00-6P 143804-01-7P 143804-02-8P 143804-03-9P, N-(2-Morpholinomethyl)butyramidine 143804-04-0P, N-(5-Methylthio-2-morpholinophenyl)isobutyramidine 143804-05-1P, 4-[2-(3-Morpholinylideneamino)phenyl]morpholine 143804-06-2P 143804-07-3P 143804-08-4P, 2-(2-Morpholinomethyl)-1,1,3,3-tetramethylguanidine 143804-09-5P, 4-(2-[1-(2-Formyloxyethyl)-2-imidazolidinylideneamino]phenyl)morpholine 143804-10-8P, 1-(2-Methoxyethyl)-2-(2-piperidinylphenyl)guanidine 143804-11-9P, 1-Methyl-3-[2-(1-pyrrolidinyl)phenyl]urea 143804-12-0P, 1-Methyl-3-(5-methyl-2-morpholinophenyl)urea 143804-13-1P, 1-Methyl-2-(2-morpholinophenyl)-3-pentylguanidine 143804-14-2P 143804-15-3P 143804-16-4P, 4-[2-(1,3-Dimethyl-2-imidazolidinylideneamino)benzyl]morpholine 144187-06-4P, 4-[2-(2-Piperidinylideneamino)phenyl]morpholine maleate 144187-07-5P 144187-08-6P 144187-09-7P 144187-11-1P 144187-12-2P 144187-13-3P 144187-14-4P, 1,1-Dimethyl-2-(5-methyl-2-morpholinophenyl)guanidine monotartrate 144187-15-5P, 1,1-Dimethyl-2-(2-morpholinophenyl)guanidine hemisulfate 144187-16-6P, 1,1-Dimethyl-2-(2-morpholinophenyl)guanidine hemipamoate 144187-17-7P, N-(2-Morpholinomethyl)butyramidine fumarate 144187-19-9P, N-Methyl-N'-(2-morpholinomethylbenzyl)neopentanamidine monofumarate 144187-20-2P, 4-(2-[1-(2-Benzoyloxyethyl)-3-methyl-2-imidazolidinylideneamino]phenyl)morpholine monofumarate 144187-21-3P 144187-22-4P, 1,3,3-Trimethyl-2-(2-morpholinophenyl)guanidine monofumarate 144187-23-5P, 1-Butyl-2-(2-morpholinophenyl)-3-methylguanidine monofumarate 144187-24-6P, 1-(2-Methoxyethyl)-2-(2-piperidinophenyl)guanidine hemifumarate 144187-25-7P, 1-Methyl-2-(2-morpholinophenyl)-3-(2-methoxyethyl)guanidine hemifumarate 144187-26-8P, 1-Allyl-2-[2-(1-pyrrolidinyl)phenyl]-3-methylguanidine monofumarate 144187-27-9P, 4-(2[-1-(2-Hydroxyethyl)-2-imidazolidinylideneamino]-4-methylphenyl)morpholine.2/3 fumarate 144187-28-0P, 1-Methyl-2-(2-morpholinophenyl)-3-valeramidine monofumarate 144187-29-1P, 2-Methyl-1-(6-methyl-2-morpholinophenyl)-3-methyl-2-thiopseudourea hydriodide 144187-32-6P, N,N-Dimethyl-N'-(2-morpholinomethylphenyl)guanidine monofumarate
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, as hypoglycemic)

IT 80-73-9P, 1,3-Dimethyl-2-imidazolidinone 1530-89-8P, 4-Cyanomorpholine 3699-54-5P, 1-(2-Hydroxyethyl)-2-imidazolinone 51317-68-1P, 2-Piperidinophenyl isothiocyanate 67829-55-4P, 1-[2-(1-Pyrrolidinyl)phenyl]urea 95539-61-0P, 4-(2-Aminobenzyl)morpholine 131679-04-4P 131679-05-5P 131679-06-6P 131679-08-8P, 1-[2-(4-Morpholino)phenyl]thiourea 131679-09-9P 131679-12-4P 131679-13-5P, 2-[Bis(2-methoxyethyl)amino]phenyl isothiocyanate 131679-14-6P 131679-15-7P 131679-16-8P, 2-Thiamorpholinophenyl isothiocyanate 131679-18-0P 131679-21-5P 131679-22-6P, 5-Methyl-2-morpholinophenyl isothiocyanate 131679-23-7P, 1-(5-Methyl-2-morpholinophenyl)thiourea 131679-24-8P, 1-[2-(2-Methyl-1-pyrrolidinyl)phenyl]thiourea 131679-25-9P 131679-26-0P, 1-(2-Piperidinophenyl)thiourea 131679-27-1P 131679-28-2P, 6-Methyl-2-piperidinophenyl isocyanate 131679-29-3P 131679-30-6P, N-(2-Hydroxyethyl)-1,2-dimethyl-1,2-ethylenediamine 131679-31-7P, 1-(2-Morpholinophenyl)-3-methylthiourea 131679-32-8P, 2-Methyl-1-(2-morpholinophenyl)guanidine 131679-36-2P 131679-44-2P 131679-50-0P 131679-52-2P 131679-53-3P 131679-54-4P 131679-55-5P 131679-56-6P 131679-57-7P 131679-58-8P 131679-59-9P 131679-60-2P 131679-61-3P 131679-62-4P 131679-63-5P 131679-64-6P, N-(2-Morpholinophenyl)-N-cyanoamine 131679-65-7P, N-Methyl-N'-(2-morpholinophenyl)carbodiimide 131679-66-8P 131679-67-9P 131698-05-0P, 1-(6-Methyl-2-piperidinophenyl)thiourea 131698-06-1P 144187-33-7P, 6-Methyl-2-morpholinophenyl isothiocyanate 144187-34-8P,

1-(6-Methyl-2-morpholinophenyl)urea 144187-36-0P, 1-(2-Thiamorpholinophenyl)urea 144187-37-1P, 3-Benzoyl-1-[2-(1-pyrrolidinyl)phenyl]urea 144187-38-2P 144187-39-3P, 1-Ethyl-3-(2-morpholinophenyl)urea 144187-40-6P 144187-41-7P, 1-Butyl-3-(2-morpholinophenyl)pseudourea 144187-58-6P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, as intermediate for hypoglycemics)

IT 57-13-6, Urea, reactions 74-88-4, Methyl iodide, reactions 75-21-8, Oxirane, reactions 78-82-0, Isobutyronitrile 80-48-8, Methyl p-toluenesulfonate 93-97-0, Benzoyl anhydride 107-15-3, 1,2-Ethanediamine, reactions 109-11-5, 3-Morpholinone 109-73-9, Butylamine, reactions 109-74-0, Butyronitrile 109-81-9 110-59-8, Valeronitrile 110-60-1, 1,4-Butanediamine 111-41-1, N-(2-Hydroxyethyl)-1,2-ethylenediamine 124-40-3, Dimethylamine, reactions **130-85-8**, Pamoic acid 463-71-8, Thiophosgene 532-55-8, Benzoyl isothiocyanate 556-61-6, Methyl isothiocyanate 563-86-0, 1,2-Dimethylethylenediamine 592-82-5, Butyl isothiocyanate 630-18-2 632-22-4, Tetramethylurea 675-20-7, 2-Piperidinone 784-57-6, 2-Morpholino-5-(trifluoromethyl)aniline 872-50-4, 1-Methyl-2-pyrrolidinone, reactions 1003-03-8, Cyclopentylamine 1467-79-4, N,N-Dimethylcyanamide 5370-33-2, 1,3,3-Trimethyl-2-pyrrolidinone 5448-29-3, N'-Isopropyl-2-methyl-1,2-propanediamine 5585-33-1 6291-84-5, 3-(Methylamino)propylamine 6830-83-7 21627-58-7, 1-(2-Aminophenyl)pyrrolidine 22455-69-2 26586-18-5, 4-(2-Amino-4-methoxycarbonylphenyl)morpholine 39643-31-7, 2-Piperidinoaniline 39799-78-5, 1,3-Dimethyl-2-imidazolinone 50533-97-6, 4-(Dimethylamino)piperidine 51317-67-0 59504-49-3 84186-31-2, 6-Methyl-2-piperidinoaniline 90875-44-8, 4-(2-Amino-4-chlorophenyl)morpholine 91429-92-4, 4-(2-Amino-4-methylphenyl)morpholine 108303-99-7, 1-Benzyl-3-methyl-2-pyrrolidinone 113502-25-3, 3-Ethyl-1,1,3-trimethylurea 131679-48-6, 2-Morpholino-5-(trimethylmethyl)phenyl isothiocyanate 131679-49-7 144187-42-8, 1-Methyl-3-(2-methoxyethyl)-2-piperidinone 144187-43-9, 5-(Methylthio)-2-morpholinoaniline 144187-44-0, 5-Fluoro-2-morpholinoaniline 144187-45-1, 4-(2-Amino-4-chlorobenzyl)morpholine 144187-46-2, 3-Allyl-2-(2-morpholinophenyl)-1,3,3-trimethylurea 144187-47-3, 3-Butyl-1,1,3-trimethylurea 144187-48-4 144187-50-8, 6-Methyl-2-morpholinoaniline 144187-51-9, N,N-Bis(2-methoxyethyl)benzene-1,2-diamine 144187-52-0, 2-Thiomorpholinoaniline 144187-53-1, 2-Methyl-1-(2-aminophenyl)pyrrolidine 144187-54-2 144187-55-3, 4-(2-Aminophenyl)morpholine hydrochloride 144187-56-4, 4-Methoxy-2-morpholinoaniline 144187-57-5, 5-Isobutyl-2-morpholinoaniline hydrochloride
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, in prepn. of hypoglycemics)

IT **130-85-8**, Pamoic acid
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, in prepn. of hypoglycemics)

RN 130-85-8 HCAPLUS

CN 2-Naphthalenecarboxylic acid, 4,4'-methylenebis[3-hydroxy- (9CI) (CA INDEX NAME)



```
=> fil reg
FILE 'REGISTRY' ENTERED AT 12:15:11 ON 10 MAY 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:    9 MAY 2003  HIGHEST RN 513416-44-9
DICTIONARY FILE UPDATES:   9 MAY 2003  HIGHEST RN 513416-44-9

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2003

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

Crossover limits have been increased.  See HELP CROSSOVER for details.

Experimental and calculated property data are now available.  See HELP
PROPERTIES for more information.  See STNote 27, Searching Properties
in the CAS Registry File, for complete details:
http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

=> d sta que l25
L20             STR
```



```
NODE ATTRIBUTES:
CONNECT IS M1  RC AT  12
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC  17   8
NUMBER OF NODES IS  24
```

STEREO ATTRIBUTES: NONE
L22 STR



NODE ATTRIBUTES:
CONNECT IS E1 RC AT 14
CONNECT IS E2 RC AT 16
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC 17 8
NUMBER OF NODES IS 19

STEREO ATTRIBUTES: NONE
L24 95 SEA FILE=REGISTRY SSS FUL L22
L25 0 SEA FILE=REGISTRY SUB=L24 SSS FUL L20

100.0% PROCESSED 1 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

=> fil marpat
FILE 'MARPAT' ENTERED AT 12:15:38 ON 10 MAY 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 American Chemical Society (ACS)

FILE CONTENT: 1988-PRESENT (VOL 104 ISS 15-VOL 138 ISS17)(20030425/ED)

MOST RECENT CITATIONS FOR PATENTS FROM FIVE MAJOR ISSUING AGENCIES
(COVERAGE TO THESE DATES IS NOT COMPLETE):

US 6541517 01 APR 2003
DE 10240388 20 MAR 2003
EP 1297829 02 APR 2003
JP 2003100285 04 APR 2003
WO 2003028051 03 APR 2003

Structure search limits have been raised. See HELP SLIMIT for the new, higher limits.

=> d sta que l33
L27 STR



NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC 17 8
NUMBER OF NODES IS 24

STEREO ATTRIBUTES: NONE
L29 3 SEA FILE=MARPAT SSS FUL L27
L30 STR



NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED
ECOUNT IS M5 C AT 16

GRAPH ATTRIBUTES:
RSPEC 17 8
NUMBER OF NODES IS 24

STEREO ATTRIBUTES: NONE
L32 3 SEA FILE=MARPAT SUB=L29 SSS FUL L30
L33 2 SEA FILE=MARPAT ABB=ON PLU=ON L32 AND ("120:322935"/AN OR "123:188623"/AN)

=> d scan l33

L33 2 ANSWERS MARPAT COPYRIGHT 2003 ACS
IC ICM A61K031-41
ICS A61K031-35; A61K031-355; A61K031-19; A61K031-165
CC 1-11 (Pharmacology)
TI Use of PLA2 inhibitors as treatment for Alzheimers disease
ST phospholipase A2 inhibitor Alzheimers
IT Mental disorder
(Alzheimer's disease, phospholipase A2 inhibitors for treatment of Alzheimers disease)
IT Molecular structure-biological activity relationship

(phospholipase A2-inhibiting, phospholipase A2 inhibitors for treatment of Alzheimers disease)

IT 117690-79-6P 131476-18-1P 147612-00-8P 152607-95-9P 152607-96-0P
152607-97-1P 152608-00-9P 152608-30-5P 152608-31-6P 152609-76-2P
153034-72-1P 153226-99-4P 155453-14-8P 156005-50-4P 156141-16-1P
161172-51-6P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(phospholipase A2 inhibitors for treatment of Alzheimers disease)

IT 9001-84-7, Phospholipase A2
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(phospholipase A2 inhibitors for treatment of Alzheimers disease)

IT 89-84-9 108-46-3, 1,3-Benzenediol, reactions 151-10-0, 1,3-Dimethoxybenzene 627-30-5, 3-Chloropropanol 1765-93-1, 4-Fluorophenylboronic acid 2498-25-1, 2-Dimethylaminoethanol hydrochloride 3017-96-7, 1-Bromo-2-chloropropane 4460-42-8 29290-79-7 97305-10-7 152609-60-4
RL: RCT (Reactant); RACT (Reactant or reagent)
(phospholipase A2 inhibitors for treatment of Alzheimers disease)

IT 535-11-5P, Ethyl 2-bromopropanoate 2896-60-8P, 4-Ethylresorcinol 13331-19-6P, 1,3-Benzenediol, 2-propyl- 16929-64-9P, 1,3-Dimethoxy-2-propylbenzene 29682-12-0P 37470-83-0P, 2,4-Dihydroxy-5-ethylbenzaldehyde 147611-86-7P 147611-94-7P 147611-95-8P 147611-96-9P 147611-97-0P 147611-98-1P 147611-99-2P 152120-06-4P 152120-07-5P 152120-09-7P 152120-26-8P 152120-27-9P 152607-82-4P 152607-99-3P 152608-41-8P 152609-39-7P 152609-40-0P 152609-41-1P 152609-63-7P 152609-64-8P 152609-65-9P 152609-66-0P 152609-67-1P 152609-68-2P 152609-83-1P 152609-84-2P 155219-33-3P 155219-34-4P 155219-35-5P 157230-37-0P 157230-42-7P 157230-43-8P 167770-20-9P 167770-21-0P 167770-22-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(phospholipase A2 inhibitors for treatment of Alzheimers disease)

MSTR 1



G1 = OEt
G5 = 42-5 43-11



G6 = (3-9) CH2
G12 = 379



DER: or pharmaceutically acceptable salts or solvates
MPL: claim 3

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):

L33 2 ANSWERS MARPAT COPYRIGHT 2003 ACS
IC ICM C07D311-66
ICS C07D257-04; A61K031-35; A61K031-41
CC 25-17 (Benzene, Its Derivatives, and Condensed Benzenoid Compounds)
Section cross-reference(s): 1
TI Preparation of 1,2,4-trihydroxybenzene derivatives as leukotriene antagonists
ST hydroxybenzene deriv prepn leukotriene antagonist; antiasthmatic trihydroxybenzene deriv prepn
IT Leukotrienes
RL: RCT (Reactant); RACT (Reactant or reagent)
(antagonists, antagonists of, trihydroxybenzene derivs. as)
IT Bronchodilators
(antiasthmatics, trihydroxybenzene derivs.)
IT 71160-24-2, Leukotriene B4
RL: RCT (Reactant); RACT (Reactant or reagent)
(antagonists of, trihydroxybenzene derivs. as)
IT 29682-12-0P, 4-Benzyloxy-2-hydroxy-1-acetophenone 37470-83-0P, 5-Ethyl-2,4-dihydroxybenzaldehyde 147527-86-4P 147527-87-5P 147527-88-6P 147527-89-7P 147527-90-0P 147527-91-1P 147527-92-2P 147527-93-3P 147527-94-4P 147527-95-5P 147527-96-6P 147527-97-7P 147527-98-8P 147527-99-9P 147528-00-5P 147528-01-6P 147528-02-7P 147528-03-8P, 2-Cyano-2-methyl-7-hydroxyheptane 147611-86-7P 147611-87-8P 147611-88-9P 147611-89-0P 147611-90-3P 147611-91-4P 147611-92-5P 147611-94-7P 147611-95-8P 147611-96-9P 147611-97-0P 147611-98-1P 147611-99-2P 152120-06-4P 152609-39-7P 152609-40-0P 154878-07-6P 154878-08-7P 154878-09-8P 154878-10-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and reaction of, in prepn. of leukotriene antagonist)
IT 147527-80-8P 147527-83-1P 147527-84-2P 147527-85-3P 147555-12-2P 147611-93-6P 147612-00-8P 154877-96-0P 154877-97-1P 154877-98-2P 154877-99-3P 154878-00-9P 154878-01-0P 154878-02-1P 154878-03-2P 154878-04-3P 154878-05-4P 154878-06-5P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of, as leukotriene antagonist)
IT 89-84-9, 2,4-Dihydroxyacetophenone 100-39-0, Benzyl bromide 106-95-6, Allyl bromide, reactions 627-30-5, 3-Chloropropanol 882-33-7, Diphenyl disulfide 2896-60-8, 4-Ethylresorcinol 140660-32-8
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, in prepn. of leukotriene antagonist)

MSTR 1



G1 = O
G2 = Me
G10 = alkylene<(1-10)>
G11 = O
G24 = 181



G41 = Ak<EC (2) C, BD (0-) D (0-) T>
DER: or pharmaceutically acceptable base addition salts
MPL: claim 1
NTE: substitution is restricted

ALL ANSWERS HAVE BEEN SCANNED

=> fil hcaplus
FILE 'HCAPLUS' ENTERED AT 12:16:00 ON 10 MAY 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 10 May 2003 VOL 138 ISS 20
FILE LAST UPDATED: 9 May 2003 (20030509/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d bib abs 134 tot

L34 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2003 ACS
AN 1995:792781 HCAPLUS
DN **123:188623**
TI Use of PLA2 inhibitors as treatment for Alzheimers disease
IN Clemens, James Allen; Sofia, Michael Joseph; Stepenson, Diane Teresa

PA Lilly, Eli, and Co., USA
SO PCT Int. Appl., 91 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9517183	A1	19950629	WO 1994-US14504	19941214
	W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LT, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, UZ, VN				
	RW: KE, MW, SD, SZ, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	US 5478857	A	19951226	US 1993-173544	19931223
	CA 2179649	AA	19950629	CA 1994-2179649	19941214
	AU 9514028	A1	19950710	AU 1995-14028	19941214
	AU 688446	B2	19980312		
	EP 735870	A1	19961009	EP 1995-905404	19941214
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	CN 1142768	A	19970212	CN 1994-195027	19941214
	HU 75335	A2	19970528	HU 1996-1741	19941214
	JP 09507069	T2	19970715	JP 1994-517514	19941214
	BR 9408407	A	19970805	BR 1994-8407	19941214
	ZA 9410041	A	19960618	ZA 1994-10041	19941215
	US 5563164	A	19961008	US 1995-464030	19950605
	NO 9602568	A	19960809	NO 1996-2568	19960617
	FI 9602557	A	19960822	FI 1996-2557	19960619
PRAI	US 1993-173544		19931223		
	WO 1994-US14504		19941214		

OS MARPAT 123:188623
GI



I

AB This invention provides methods for the treatment or prevention of Alzheimer's disease in a mammal which comprises administering to a mammal in need thereof an effective amt. of an inhibitor of phospholipase A2 (PLA2), esp. cytosolic PLA2. E.g., I was prepd. and shows good PLA2 inhibitory activity. Pharmaceutical formulations are also given.

L34 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2003 ACS
AN 1994:322935 HCAPLUS
DN **120:322935**
TI Preparation of 1,2,4-trihydroxybenzene derivatives as leukotriene antagonists
IN Sofia, Michael Joseph
PA Lilly, Eli, and Co., USA
SO Eur. Pat. Appl., 53 pp.
CODEN: EPXXDW
DT Patent

LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 579412	A1	19940119	EP 1993-305090	19930629
	EP 579412	B1	19981007		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
	US 5352690	A	19941004	US 1992-907492	19920701
	CA 2095487	AA	19940102	CA 1993-2095487	19930504
	JP 06080566	A2	19940322	JP 1993-154990	19930625
	ES 2121949	T3	19981216	ES 1993-305090	19930629
PRAI	US 1992-907492		19920701		

OS MARPAT 120:322935
GI



I



II

AB Title compds. [I; A = bond, O, S, CH:CH, etc.; D = O or S; R1 = (cyclo)alkyl, (substituted)Ph; R2 = alk(en)yl, alkynyl, alkoxy; R3 = CO2H, tetrazol-5-yl, etc.; X = O, S, CO, CH2; Y = O, CH2; XY = CH:CH, C.tplbond.C; Z = bond, alkylidenyl(sic)] were prepd. Thus, 5-ethyl-2,4-dihydroxybenzaldehyde was condensed with Et 3,4-dihydro-7-[1-(3-hydroxypropropoxy)]-8-propyl-2H-1-benzopyran-2-carboxylate (prepn. each given) and the product converted in 5 steps to title compd. II which had IC50 of 2.9nM against LTB4 binding to human neutrophils in vitro.

=> d his

(FILE 'HOME' ENTERED AT 11:38:17 ON 10 MAY 2003)
SET COST OFF

FILE 'HCAPLUS' ENTERED AT 11:38:27 ON 10 MAY 2003
E HELMERHORST E/AU
L1 20 S E3-E5
E PLEWRIGHT B/AU
L2 2 S E4,E5
E CURTIN/PA,CS
L3 3931 S E3-E56
L4 6 S L1,L2 AND L3
L5 2 S L1 AND L2
SEL DN AN 2
L6 1 S L5 AND E1-E3
SEL RN

```
     FILE 'REGISTRY' ENTERED AT 11:40:02 ON 10 MAY 2003
L7            14 S E4-E17
L8            13 S L7 NOT INSULIN
L9          1416 S (591.146.33 AND 46.150.18)/RID AND 3/NR AND 5/O AND 1/NC NOT
L10            4 S L9 AND 2 CARBOXYLIC ACID
L11          480 S (591.146.33 AND 46.150.18)/RID AND 2 CARBOXYLIC ACID
L12           19 S L11 AND 4 METHOXY
L13        16711 S (591.146.33 AND 46.150.18)/RID AND 3/NR
L14          300 S L13 AND 26/C
L15           50 S L14 AND 5/O
L16           31 S L15 NOT N/ELS

     FILE 'HCAPLUS' ENTERED AT 11:53:06 ON 10 MAY 2003
L17           19 S L1,L2 NOT L6
                 SEL RN

     FILE 'REGISTRY' ENTERED AT 11:53:12 ON 10 MAY 2003
L18           16 S E18-E33
L19            0 S L18 AND L13
L20              STR
L21            0 S L20 CSS
L22              STR L20
L23            2 S L22
L24           95 S L22 FUL
                 SAV L24 HOPE400/A
L25            0 S L20 FUL SUB=L24
                 SAV L25 HOPE400A/A

     FILE 'MARPAT' ENTERED AT 11:58:35 ON 10 MAY 2003
L26            0 S L20 SAM
L27              STR L20
L28            0 S L27 SAM
L29            3 S L27 FUL
                 SAV L29 HOPE400B/A
L30              STR L27
L31            0 S L30 SAM SUB=L29
L32            3 S L30 FUL SUB=L29
                 SEL AN 2 3
L33            2 S L32 AND E34-E35

     FILE 'HCAPLUS' ENTERED AT 12:03:06 ON 10 MAY 2003

     FILE 'MARPAT' ENTERED AT 12:03:14 ON 10 MAY 2003
                 EDIT E34-E35 /AN /DCN

     FILE 'HCAPLUS' ENTERED AT 12:03:26 ON 10 MAY 2003

     FILE 'MARPAT' ENTERED AT 12:03:40 ON 10 MAY 2003
                 SEL AN L33
                 EDIT E36-E37 /AN /DN

     FILE 'HCAPLUS' ENTERED AT 12:04:01 ON 10 MAY 2003
L34            2 S E36-E37

     FILE 'REGISTRY' ENTERED AT 12:04:48 ON 10 MAY 2003

     FILE 'HCAPLUS' ENTERED AT 12:05:06 ON 10 MAY 2003
L35         1473 S L8
L36            1 S L35 AND L1,L2
L37            2 S L35 AND L3
L38            2 S L36,L37

     FILE 'REGISTRY' ENTERED AT 12:05:59 ON 10 MAY 2003
```

```
L39           2 S INSULIN/CN OR "INSULIN (HUMAN)"/CN
L40        6584 S INSULIN NOT L39

     FILE 'HCAPLUS' ENTERED AT 12:06:36 ON 10 MAY 2003
L41       87121 S L39
L42       31398 S L40

     FILE 'REGISTRY' ENTERED AT 12:06:48 ON 10 MAY 2003
L43           2 S GLUCOSE/CN

     FILE 'HCAPLUS' ENTERED AT 12:06:50 ON 10 MAY 2003
L44      149193 S L43
L45      350750 S GLUCOSE
L46           9 S L35 AND L41
L47          23 S L35 AND L42
L48          12 S L35 AND L44
L49          34 S L35 AND L45
                E INSULIN RECEPTOR/CT
                E E18+ALL
L50        9735 S E8,E7+NT
L51           8 S L35 AND L50
L52           7 S L51 AND L46-L49
                E PHARMACOPHOR/CT
                E E4+ALL
L53        1650 S E2
L54           3 S L53 AND L35
L55           9 S L51,L52,L54 NOT L38
                E DIABETES/
                E DIABETES/CT
                E E3+ALL
L56        7010 S E1
                E E2+ALL
L57        1390 S E2
                E DIABETES/CT
                E E10+ALL
L58       48188 S E4+NT
                E E9+ALL
                E E14+ALL
                E DIABETES/CT
                E E10+ALL
                E E9+ALL
L59       12052 S E4,E5,E3+NT
L60           1 S L38 AND L56-L59
L61           0 S L60 NOT L38
L62          60 S L46-L49,L55 NOT L38
L63          43 S L62 AND (PHARMACEUT? OR PHARMACOL?)/SC,SX
L64          16 S L8 (L) THU/RL AND L63
L65           0 S L64 AND ?DIABET?
L66           1 S L62 AND ?DIABET?
L67           1 S L66 AND L1-L6,L17,L35-L38,L41,L42,L44-L66

     FILE 'REGISTRY' ENTERED AT 12:15:11 ON 10 MAY 2003

     FILE 'MARPAT' ENTERED AT 12:15:38 ON 10 MAY 2003

     FILE 'HCAPLUS' ENTERED AT 12:16:00 ON 10 MAY 2003

=> fil uspatall
FILE 'USPATFULL' ENTERED AT 12:31:23 ON 10 MAY 2003
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 12:31:23 ON 10 MAY 2003
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)
```

=> d l23 bib abs kwic hitstr tot

L23 ANSWER 1 OF 2 USPATFULL
AN 2001:205933 USPATFULL
TI Nitrosated and nitrosylated cyclooxygenase-2 inhibitors, compositions and methods of use
IN Bandarage, Ramani R., Newton, MA, United States
Bandarage, Upul K., Newton, MA, United States
Fang, Xinqin, Lexington, MA, United States
Garvey, David S., Dover, MA, United States
Letts, L. Gordon, Dover, MA, United States
Schroeder, Joseph D., Dedham, MA, United States
Tam, Sang William, Dover, MA, United States
PI US 2001041726 A1 20011115
AI US 2000-741816 A1 20001222 (9)
PRAI US 2000-226085P 20000818 (60)
US 1999-171623P 19991223 (60) <--
DT Utility
FS APPLICATION
LREP EDWARD D GRIEFF, HALE & DORR LLP, 1455 PENNSYLVANIA AVE, NW, WASHINGTON, DC, 20004
CLMN Number of Claims: 70
ECL Exemplary Claim: 1
DRWN 5 Drawing Page(s)
LN.CNT 6284
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention describes novel nitrosated and/or nitrosylated cyclooxygenase 2 (COX-2) inhibitors and novel compositions comprising at least one nitrosated and/or nitrosylated cyclooxygenase 2 (COX-2) inhibitor, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or optionally, at least one therapeutic agent, such as, steroids, nonsteroidal antiinflammatory compounds (NSAID), 5-lipoxygenase (5-LO) inhibitors, leukotriene B.sub.4 (LTB.sub.4) receptor antagonists, leukotriene A.sub.4 (LTA.sub.4) hydrolase inhibitors, 5-HT agonists, 3-hydroxy-3-methylglutaryl coenzyme A (HMGCoA) inhibitors, H antagonists, antineoplastic agents, antiplatelet agents, decongestants, diuretics, sedating or non-sedating anti-histamines, inducible nitric oxide synthase inhibitors, opioids, analgesics, Helicobacter pylori inhibitors, proton pump inhibitors, isoprostane inhibitors, and mixtures thereof. The present invention also provides novel compositions comprising at least one parent COX-2 inhibitor and at least one nitric oxide donor, and, optionally, at least one therapeutic agent. The present invention also provides kits and methods for treating inflammation, pain and fever; for treating and/or improving the gastrointestinal properties of COX-2 inhibitors; for facilitating wound healing; for treating and/or preventing renal toxicity; and for treating and/or preventing other disorders resulting from elevated levels of cyclooxygenase-2.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
PRAI US 1999-171623P 19991223 (60) <--
DETD . . . (Leo Denmark); MAFP (Merck); TMK-688 (Terumo); T-0757 (Tanabe); LY 213024, LY 210073, LY 223982, LY 233469, LY 255283, LY 264086, **LY 292728** and LY 293111 (Eli Lilly); ONO-LB457, ONO-4057, and ONO-LB-448 (ONO), S-2474, calcitrol (Shionogi); PF 10042 (Perdu Frederick); Pfizer 105696 (Pfizer. . .
DETD . . . such as, for example, vascular diseases, migraine headaches, periarteritis nodosa, thyroiditis, aplastic anemia, Hodgkin's disease, sclerodoma, rheumatic fever, type I **diabetes**, neuromuscular

junction disease including myasthenia gravis, white matter disease including multiple sclerosis, sarcoidosis, nephrotic syndrome, Behcet's syndrome, polymyositis, gingivitis, nephritis,. . .

L23 ANSWER 2 OF 2 USPATFULL
AN 1998:122433 USPATFULL
TI Leukotriene antagonists for use in the treatment or inhibition of cerebral focal stroke
IN Fleisch, Jerome H., Carmel, IN, United States
Jackson, William T., Indianapolis, IN, United States
Sawyer, Jason S., Indianapolis, IN, United States
PA Eli Lilly and Company, Indianapolis, IN, United States (U.S. corporation)
PI US 5817684 19981006 <--
AI US 1997-982600 19971202 (8)
PRAI US 1996-33180P 19961213 (60) <--
US 1997-40872P 19970321 (60) <--
DT Utility
FS Granted
EXNAM Primary Examiner: Schenkman, Leonard
LREP Palmberg, Arleen, Boone, David E.
CLMN Number of Claims: 14
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1047
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention provides methods for the treatment or prevention of cerebral focal ischemia which comprises administering to a mammal in need thereof an effective amount of a compound having activity as a leukotriene B.sub.4 antagonist.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
PI US 5817684 19981006 <--
PRAI US 1996-33180P 19961213 (60) <--
PRAI US 1997-40872P 19970321 (60) <--
DETD . . . of cranial blood vessels. By far, the most common cause of cerebral thrombosis is atherosclerosis, very often associated with hypertension, **diabetes** mellitus, and coronary artery or peripheral vascular disease. Inflammatory blood vessel disorders, which occur in syphilis, tuberculosis, temporal arteritis, or. . .
DETD Stroke usually can be diagnosed clinically, especially in a person over age 50 with hypertension, **diabetes** mellitus, or signs of atherosclerosis, or in anyone with a known source of emboli. In the unusual case, differentiation from. . .
IT 152608-02-1 **153034-77-6** 160283-57-8 161172-51-6
185394-59-6
(leukotriene B4 antagonist prepn. for treatment or inhibition of cerebral focal stroke)
IT **153034-77-6**
(leukotriene B4 antagonist prepn. for treatment or inhibition of cerebral focal stroke)
RN 153034-77-6 USPATFULL
CN 9H-Xanthene-4-propanoic acid, 7-carboxy-3-[3-[(5-ethyl-4'-fluoro-2-hydroxy[1,1'-biphenyl]-4-yl)oxy]propoxy]-9-oxo- (9CI) (CA INDEX NAME)


HO2C— CH2— CH2
O
O— (CH2)3— O
Et
F
OH
HO2C
O